Printer Friendly

FDA approves first generic versions of Lamisil tablets.

The FDA has approved the first generic versions of prescription Lamisil (terbinafine hydrochloride) tablets, used to treat nail fungus infection (onychomycosis). Such infections occur when fungi invade a fingernail or toenail or the skin underneath the nail.

"This approval offers Americans additional alternatives when choosing medications to treat nail fungus infections," Said Gary J. Buehler, R.Ph., director of FDA's Office of Generic Drugs.

FDA approved applications from multiple generic drug manufacturers for terbinafine hydrochloride tablets in 250-milligram formulations. Manufacturers include: Amneal Pharmaceuticals, Apotex Corp., Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter USA Inc., Genpharm Inc., Glenmark Pharmaceuticals Inc., InvaGen Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Orgenus Pharma Inc., Roxane Laboratories Inc., TEVA Pharmaceuticals USA, Watson Laboratories Inc., Wockhardt USA Inc.

In addition to terbinafine tablets, FDA also approved an application for a generic version of over-the-counter Lamisil cream (terbinafine hydrochloride, 1 percent) to treat athlete's foot, a skin disease caused by a fungus that usually occurs between the toes. The cream is manufactured by Taro Pharmaceuticals U.S.A Inc.
COPYRIGHT 2007 Advantage Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry News
Publication:Pharmaceutical Processing
Date:Aug 1, 2007
Previous Article:PennTech Machinery and Shanghai Tofflon sign joint venture.
Next Article:Glatt to host solid dosage symposium.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters